Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) have been given an average recommendation of “Buy” by the six brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $260.00.

A number of brokerages have recently issued reports on BIO. Deutsche Bank AG reaffirmed a “buy” rating and issued a $255.00 price target on shares of Bio-Rad Laboratories in a research note on Monday, September 18th. Zacks Investment Research lowered Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research note on Thursday, October 12th. TheStreet lowered Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, August 3rd. Wells Fargo & Co began coverage on Bio-Rad Laboratories in a research note on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price target on the stock. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $275.00 price target on shares of Bio-Rad Laboratories in a research note on Friday, July 14th.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/21/bio-rad-laboratories-inc-bio-receives-consensus-recommendation-of-buy-from-analysts-2.html.

In other news, EVP Michael Crowley sold 700 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $215.91, for a total value of $151,137.00. Following the sale, the executive vice president now directly owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 28.29% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Investment Management Company LLC boosted its stake in Bio-Rad Laboratories by 0.4% during the second quarter. Northwestern Mutual Investment Management Company LLC now owns 3,596 shares of the medical research company’s stock worth $514,000 after buying an additional 13 shares during the last quarter. World Asset Management Inc boosted its stake in Bio-Rad Laboratories by 1.4% during the second quarter. World Asset Management Inc now owns 1,025 shares of the medical research company’s stock worth $232,000 after buying an additional 14 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in Bio-Rad Laboratories by 1.8% during the second quarter. Teacher Retirement System of Texas now owns 1,666 shares of the medical research company’s stock worth $377,000 after buying an additional 29 shares during the last quarter. US Bancorp DE boosted its stake in Bio-Rad Laboratories by 0.8% during the second quarter. US Bancorp DE now owns 4,224 shares of the medical research company’s stock worth $956,000 after buying an additional 34 shares during the last quarter. Finally, State of Wisconsin Investment Board boosted its stake in Bio-Rad Laboratories by 1.0% during the second quarter. State of Wisconsin Investment Board now owns 4,187 shares of the medical research company’s stock worth $948,000 after buying an additional 40 shares during the last quarter. 62.84% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories (NYSE:BIO) opened at 221.94 on Friday. Bio-Rad Laboratories has a one year low of $154.89 and a one year high of $242.79. The company has a market cap of $6.58 billion, a PE ratio of 438.62 and a beta of 0.91. The stock has a 50 day moving average of $223.03 and a 200 day moving average of $221.75.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.